Core Insights - Veracyte (VCYT) is positioned for growth due to strong sales momentum from its Afirma and Decipher Prostate tests, alongside a solid financial health profile [1][8] - The company faces operational challenges from macroeconomic pressures and intense competition in the diagnostics sector [1][11] Financial Performance - Over the past year, VCYT stock has increased by 3%, contrasting with a 3.8% decline in the industry and a 16.4% gain in the S&P 500 [2] - Veracyte has a market capitalization of $2.38 billion and an earnings yield of 5.6%, significantly higher than the industry's -1% yield [2] - The company has consistently exceeded earnings estimates in the last four quarters, with an average surprise of 46.4% [2] Product Performance - The Afirma solution has shown a 12% volume growth in Q4 2025, driven by new account acquisitions and increased utilization [3] - The Afirma GRID offering is gaining traction in academic settings, with studies published that demonstrate its effectiveness in thyroid nodule evaluation [4] - The Decipher Prostate tests have seen a volume growth of over 20% year-over-year for 15 consecutive quarters, with approximately 27,200 tests performed in Q4 2025 [5] Strategic Developments - Veracyte is transitioning Afirma to the new V2 transcriptome, utilizing advanced next-generation sequencing technology to reduce costs and improve efficiency [4] - The Decipher Prostate test has expanded its availability to patients with metastatic prostate cancer, supported by over 100 publications validating its clinical utility [6] Liquidity and Solvency - As of Q4 2025, Veracyte reported cash and cash equivalents of $413 million with no current debt, indicating strong liquidity [10] - The company maintains a current ratio of 8.15, reflecting its ability to meet near-term obligations [10] Market Challenges - Veracyte's operations are impacted by macroeconomic factors such as rising interest rates, inflation, and geopolitical tensions, which could increase production and operating costs [11] - The competitive landscape in diagnostics is evolving, necessitating diversification in product offerings to maintain demand [12] Future Outlook - The Zacks Consensus Estimate for Veracyte's 2026 earnings per share has increased to $1.67, with projected revenues of $577.5 million, indicating an 11.7% rise from the previous year [13]

Core Viewpoint - Veracyte's recent earnings report shows significant growth in earnings and revenues, but the stock has underperformed the S&P 500, raising questions about future performance leading up to the next earnings release [1]. Financial Performance - Fourth-quarter 2025 adjusted earnings were 53 cents per share, a 47.2% increase year-over-year, beating the Zacks Consensus Estimate by 30.06% [2]. - Full-year 2025 EPS grew 49.6% year-over-year to $1.78, surpassing the Zacks Consensus Estimate by 6.2% [2]. - Revenues for Q4 increased 18.5% year-over-year to $140.6 million, exceeding the Zacks Consensus Estimate by 1.4% [3]. - Total revenues for 2025 reached $517.1 million, a 16% increase from the previous year, also surpassing the Zacks Consensus Estimate by 0.4% [3]. Segment Performance - Testing revenues in Q4 totaled $135.8 million, up 21.1% year-over-year, driven by Decipher and Afirma revenue growth of 27% and 16%, respectively [4]. - Total testing volume increased by 16% year-over-year to approximately 45,500 [4]. - Product revenues rose 27% year-over-year to $3 million in Q4 [4]. - Biopharmaceutical and other revenues decreased by 72.2% year-over-year to $962 million due to restructuring and liquidation proceedings of Veracyte SAS [5]. Margins and Expenses - Total cost of revenues was $36 million, down 3% year-over-year [6]. - Gross profit increased by 28.3% to $104.7 million, with gross margin expanding by 568 basis points to 74.4% [6]. - Selling and marketing expenses rose 4.5% to $25.9 million, while general and administrative expenses fell 35.5% to $17 million [6]. - R&D expenses totaled $20.8 million, an 8.1% increase year-over-year [6]. - Adjusted operating margin improved to 28.8% compared to 8.9% in the prior-year quarter [6]. Cash and Capital Structure - Veracyte ended Q4 2025 with cash and cash equivalents of $362.6 million, up from $239.1 million at the end of 2024 [7]. - Cumulative net cash from operating activities was $136.3 million, compared to $75.1 million a year ago [7]. Guidance - For 2026, Veracyte expects revenues between $570 million and $582 million, indicating growth of 10-13%, with testing revenues projected to increase by 14-16% [9]. - The adjusted EBITDA margin is anticipated to be 25% for 2026 [9]. Market Position - Veracyte holds a Zacks Rank 3 (Hold), indicating an expectation of an in-line return from the stock in the coming months [12]. - The company has a strong Growth Score of A but lags in Momentum Score with a C, resulting in an aggregate VGM Score of B [11].

Core Viewpoint - Veracyte, Inc. has appointed Kevin Haas, Ph.D., as Chief Development and Technology Officer to enhance its global product development strategy in cancer diagnostics [1][3] Group 1: Leadership Appointment - Kevin Haas will join Veracyte on March 24, 2026, in a newly created role focused on overseeing end-to-end product development, including diagnostic assay development, software, and bioinformatics [1][2] - Dr. Haas has over 15 years of experience in the life sciences industry, previously serving as Chief Technology Officer at Myriad Genetics, where he led the development of precision medicine platforms [3][4] Group 2: Product Development Strategy - The expansion of Veracyte's pipeline into whole-genome minimal residual disease (MRD) and multiomics applications necessitates integrated capabilities across assays, software, AI, and next-generation informatics [2] - Dr. Haas will lead efforts to deliver high-quality laboratory-developed tests (LDTs) and global in vitro diagnostic (IVD) products, aiming to accelerate innovation and support the company's global portfolio [2][3] Group 3: Company Vision and Goals - Veracyte aims to transform cancer care by providing clinicians with high-value insights for diagnosing and treating cancer, supported by a robust diagnostics platform [5][6] - The company emphasizes the importance of genomic and clinical data, bioinformatics, and AI capabilities in driving innovation and pipeline development [5][6]

Summary of Veracyte's Conference Call Company Overview - **Company**: Veracyte - **Industry**: Molecular diagnostics, specifically focused on cancer diagnostics - **Mission**: Enhance understanding of cancer and improve treatment through advanced molecular diagnostics, aiming to reach patients globally [2][3] Core Business and Financial Performance - **Revenue**: Achieved $517 million in 2025, with an 18% growth in testing revenue [5] - **Adjusted EBITDA Margin**: Exceeded 27% in 2025, surpassing the 25% target set for the year [6][26] - **Patient Reach**: Over 800,000 patients served to date, with expectations to serve the 1 millionth patient in 2026 [6][28] - **Growth Drivers**: Core business growth from Decipher and Afirma expected to support double-digit revenue growth in the foreseeable future [18] Product Portfolio Decipher Test - **Focus**: Prostate cancer prognosis and prediction, providing genomic insights to guide treatment decisions [7] - **Market Penetration**: Estimated at 33% as of the end of 2025, with significant growth potential [9] - **Volume Growth**: Achieved over 20% volume growth for 15 consecutive quarters, with a 3-year revenue CAGR of over 37% [9][10] - **Clinical Evidence**: Supported by over 100 publications, recognized in NCCN guidelines [10] Afirma Test - **Focus**: Thyroid nodule diagnosis, helping patients avoid unnecessary surgeries [15] - **Market Penetration**: Currently 38% penetrated into the Bethesda III to VI category [15] - **Volume Growth**: Experienced 11% volume growth in 2025, driven by new account wins and increased utilization [16] Upcoming Products - **TrueMRD**: Launching in 2026 for muscle invasive bladder cancer, leveraging the Decipher brand [18][22] - **Prosigna**: Expected launch in mid-2026, targeting breast cancer patients with significant market opportunity [19][20] Strategic Initiatives - **Data-Driven Approach**: Emphasizes generating more data to enhance clinical utility and adoption of tests [3][21] - **Digital Pathology and AI**: Exploring integration with molecular diagnostics, focusing on generating robust clinical evidence before commercialization [39] - **Geographic Expansion**: Plans to introduce tests like Prosigna and Decipher in Europe, addressing significant patient populations [23][24] Market Challenges and Opportunities - **Prostate Cancer**: Approximately 334,000 patients diagnosed annually in the U.S., with a growing clinical challenge [8] - **Bladder Cancer**: Strong momentum with Decipher Bladder, integrating research to guide future treatment [10][11] - **Lung Cancer**: Developing Percepta nasal swab to address early risk stratification in lung cancer patients [25] Key Takeaways - **Durability of Growth**: Confidence in sustaining growth in core business and pipeline products [40] - **Financial Strength**: Unique financial profile with strong cash generation and profitability [41] - **Underappreciated Aspects**: Core business growth, pipeline potential, and financial stability are key areas that may not be fully recognized by investors [41]

Core Insights - Veracyte, Inc. (VCYT) reported fourth-quarter 2025 adjusted earnings of 53 cents per share, a 47.2% increase year-over-year, exceeding the Zacks Consensus Estimate by 30.06% [1] - The company's GAAP earnings per share were 52 cents, compared to 7 cents in the same period last year [1] - For the full year 2025, EPS reached $1.78, marking a 49.6% increase from the previous year and surpassing estimates by 6.2% [1] Revenue Performance - Revenues for Q4 2025 increased by 18.5% year-over-year to $140.6 million, beating the Zacks Consensus Estimate by 1.4% [2] - Total revenues for 2025 were reported at $517.1 million, a 16% increase from the prior year, also surpassing estimates by 0.4% [2] - Following the earnings announcement, VCYT shares rose by 1.9% in after-hours trading [2] Segmental Revenue Breakdown - Testing revenues reached $135.8 million, up 21.1% year-over-year, driven by growth in Decipher and Afirma revenues of 27% and 16%, respectively [3] - Total testing volume was approximately 45,500, reflecting a 16% increase compared to the prior year [3] - Product revenues increased by 27% year-over-year to $3 million in Q4 [3] Margin Analysis - Total cost of revenues was $36 million, a decrease of 3% year-over-year [5] - Gross profit rose by 28.3% to $104.7 million, with gross margin expanding by 568 basis points to 74.4% [5] - Selling and marketing expenses increased by 4.5% to $25.9 million, while general and administrative expenses decreased by 35.5% to $17 million [5] Cash and Capital Structure - Veracyte ended Q4 2025 with cash and cash equivalents of $362.6 million, up from $239.1 million at the end of 2024 [6] - Cumulative net cash from operating activities was $136.3 million, compared to $75.1 million a year ago [6] Future Guidance - The company reiterated its 2026 revenue guidance of $570 million to $582 million, indicating a growth of 10-13%, with testing revenues expected to grow by 14-16% [8] - The adjusted EBITDA margin is projected to be 25% for 2026 [8] Overall Performance Assessment - Veracyte's fourth-quarter performance showed earnings and revenues exceeding estimates, supported by strong growth in the core testing business [9] - The company has seen a steady pipeline of account wins in Affirma and increased utilization per account, continuing into Q4 [9] - The transition of all Afirma volume to a more scalable, lower-cost platform and record growth in Decipher orders are positive indicators for future performance [10]

Core Insights - Veracyte, Inc. is a leading company in the cancer diagnostics field, specializing in advanced genomic tests for cancer diagnosis and treatment, with notable product lines like Decipher and Afirma [1] Financial Performance - On February 25, 2026, Veracyte reported an earnings per share (EPS) of $0.50, exceeding the estimated EPS of $0.40, indicating effective management and higher profit generation [2][6] - The company's revenue reached approximately $140.6 million, surpassing the anticipated $135.8 million, highlighting the growth of its Decipher and Afirma product lines [2][6] Market Position and Growth - In the last quarter of 2025, Veracyte served over 45,000 patients with its core testing services, demonstrating its ability to expand market presence and deliver valuable diagnostic solutions [3] - The company has a price-to-earnings (P/E) ratio of approximately 42.62, reflecting market confidence in its earnings potential [4] Financial Health - Veracyte has a low debt-to-equity ratio of 0.03, indicating minimal reliance on debt financing, and a strong current ratio of 8.15, suggesting robust liquidity [5] - The enterprise value to sales ratio is around 4.84, and the enterprise value to operating cash flow ratio is approximately 18.35, providing a comprehensive view of its valuation relative to sales and cash flow [4]

Financial Data and Key Metrics Changes - Fourth quarter total revenue was $141 million, representing a 19% year-over-year growth, driven by a 21% growth in the core testing business [5][25] - Full year total revenue reached $517 million, achieving 16% growth, with nearly 170,000 patients provided clinically actionable information [6][28] - Adjusted EBITDA margin exceeded 27% in 2025, surpassing the 25% target more than a year ahead of plan [7][28] Business Line Data and Key Metrics Changes - Decipher volume grew 21% in Q4, while Afirma grew 12%, contributing to a total testing volume growth of 16% [5][25] - Testing revenue during Q4 was $135.8 million, an increase of 21% year-over-year, with Decipher and Afirma revenue growth of 27% and 16%, respectively [25][26] - Approximately 18,250 Afirma tests were delivered in Q4, representing 12% volume growth, while Decipher tests reached approximately 27,200, marking 15 consecutive quarters of over 20% year-over-year volume growth [9][11] Market Data and Key Metrics Changes - Decipher is recognized as the only gene expression test with high-quality evidence in NCCN guidelines, contributing to its growth [12] - The market penetration for Decipher is approximately 33%, indicating significant room for growth as two-thirds of patients are still not utilizing the test [12][52] - The bladder cancer segment is currently a small portion of Decipher's total volume, but there is potential for increased use as clinical evidence develops [80] Company Strategy and Development Direction - The company plans to launch two major products in 2026: TruMRD for muscle-invasive bladder cancer and Prosigna for early-stage breast cancer [8][21] - A phased expansion strategy is in place, focusing on core business momentum and new product launches [8][24] - The company aims to sustain double-digit growth through its portfolio of tests in prostate, thyroid, bladder, and breast cancer [24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining double-digit revenue growth, supported by a strong pipeline and operational efficiencies [7][24] - The company is focused on building clinical evidence and expanding its market presence, particularly in advanced disease settings [15][19] - Management highlighted the importance of investing in growth drivers while maintaining profitability [28][46] Other Important Information - The company completed the transition of Afirma to a more scalable, lower-cost v2 transcriptome platform, improving operational efficiency [7][10] - The company has a strong cash position, ending the quarter with $412.9 million in cash and cash equivalents, providing flexibility for future investments [25][28] Q&A Session Summary Question: Guidance and Assumptions for 2026 - Management reiterated strong conviction in the 2026 guidance, with factors influencing the high and low ends of the range discussed [32][34] Question: Market Expansion for Prosigna - The potential market for Prosigna is significant, with 225,000 patients annually expected to be addressed by the indication [40] Question: Competitive Dynamics in Decipher Market - Management noted no significant changes in competitive dynamics, with Decipher continuing to show strong growth supported by clinical evidence [52][54] Question: Capital Allocation Strategy - The company maintains a deliberate approach to capital allocation, focusing on organic growth and infrastructure development [69][70]

Financial Data and Key Metrics Changes - Fourth quarter total revenue was $141 million, representing a 19% year-over-year growth, driven by a 21% growth in the core testing business [5][25] - Full year total revenue reached $517 million, achieving 16% growth, with nearly 170,000 patients provided clinically actionable information [6][28] - Adjusted EBITDA margin exceeded 27% in 2025, surpassing the 25% target more than a year ahead of plan [7][28] Business Line Data and Key Metrics Changes - Decipher volume grew 21% in Q4, with approximately 27,200 tests delivered, marking the 15th consecutive quarter of over 20% year-over-year volume growth [11][12] - Afirma delivered approximately 18,250 tests in Q4, representing a 12% volume growth, with a market share of approximately 38% [9][10] - Total testing volume for the quarter was approximately 48,000 tests, a 16% increase over the same period in 2024 [25] Market Data and Key Metrics Changes - Decipher is recognized as the only gene expression test with high-quality evidence in NCCN guidelines, contributing to its growth [12] - The bladder cancer market is transitioning towards more biologically informed evaluations, with Decipher Bladder gaining traction [18][80] - The prostate cancer market penetration for Decipher is approximately 33%, indicating significant room for growth [12][52] Company Strategy and Development Direction - The company plans to launch two major products in 2026: TruMRD for muscle-invasive bladder cancer and Prosigna for early-stage breast cancer [8][21] - A phased expansion strategy is in place, focusing on core business momentum and new product launches [8][24] - The company aims to sustain double-digit growth through its portfolio of tests in prostate, thyroid, bladder, and breast cancer [24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining double-digit growth, supported by a strong financial profile and ongoing investments in growth drivers [28][30] - The company is optimistic about the upcoming product launches and their potential to drive revenue growth [23][30] - Management highlighted the importance of generating clinical evidence to support product adoption and market penetration [16][47] Other Important Information - The company completed the transition of Afirma to a more scalable, lower-cost v2 transcriptome platform, improving operational efficiency [7][10] - The company has a strong cash position, ending the quarter with $412.9 million in cash and cash equivalents [25][28] Q&A Session Summary Question: Has the conviction in the guidance evolved in any way? - Management reiterated strong conviction in the guidance, with expectations for seasonal trends impacting Q1 performance [32][34] Question: What readout is required for the OPTIMA study to expand the intended use population? - Management indicated that the OPTIMA study includes patients with up to nine nodes, and the results will determine future market expansion [40][41] Question: Can you discuss the competitive dynamics for Decipher? - Management noted that Decipher continues to grow despite competition, with strong evidence supporting its market position [52][54]

Financial Data and Key Metrics Changes - Fourth quarter total revenue was $141 million, representing a 19% year-over-year growth driven by a strong core testing business which grew 21% [4] - Full year total revenue reached $517 million, achieving 16% growth [5] - Adjusted EBITDA margin exceeded 27% in 2025, surpassing the 25% target more than a year ahead of plan [6][29] - Cash from operations for Q4 was $52.6 million, ending the quarter with $412.9 million in cash and cash equivalents [26] Business Line Data and Key Metrics Changes - Decipher volume grew 21% in Q4, with approximately 27,200 tests delivered, marking the 15th consecutive quarter of over 20% year-over-year volume growth [11] - Afirma delivered approximately 18,250 tests in Q4, representing 12% volume growth [9] - Total testing volume for Q4 was approximately 48,000 tests, a 16% increase over the same period in 2024 [26] Market Data and Key Metrics Changes - Decipher is recognized as the only gene expression test with high-quality evidence in NCCN guidelines, contributing to its growth [12] - The market penetration for Decipher is approximately 33%, indicating significant room for growth as two-thirds of patients are not yet utilizing the test [53] - The bladder cancer market is transitioning towards more biologically informed evaluations, with Decipher Bladder being integrated into studies to guide treatment decisions [17][85] Company Strategy and Development Direction - The company plans to launch two new products in 2026: TruMRD for muscle-invasive bladder cancer and Prosigna for early-stage breast cancer [8][21] - A phased expansion strategy is in place, focusing on core business momentum and new product launches [7] - The company aims to sustain double-digit growth through its portfolio of tests across prostate, thyroid, bladder, and breast cancer [25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining double-digit growth, supported by a strong pipeline and ongoing clinical evidence generation [25][32] - The company is prepared to invest in growth drivers while maintaining profitability, with a focus on clinical evidence and product launches [46][49] - Management highlighted the importance of navigating evolving market dynamics and maintaining a strong operational model [24] Other Important Information - The company achieved significant milestones in 2025, including the launch of Decipher for metastatic patients and the transition of Afirma to a more scalable platform [5][6] - The company is on track to test its 1 millionth patient later this year, reflecting the scale and impact of its platform [5] Q&A Session Summary Question: Has your conviction in the guidance evolved in any way? - Management reiterated strong conviction in guidance, noting seasonal trends and potential drivers for high and low ends of the range [34][35] Question: What readout is required for the OPTIMA study to expand the intended use population? - Management indicated that the OPTIMA study includes enrollment criteria that could allow for expansion, pending positive results [40][42] Question: Can you walk through the push and pulls regarding the margin guidance for 2026? - Management explained that the guidance reflects the need for flexibility to invest in new product launches while maintaining profitability [45][49] Question: How is the competitive landscape for Decipher evolving? - Management noted that Decipher continues to grow despite competition, with strong evidence supporting its use in clinical guidelines [53][55] Question: What is the expected volume growth for Afirma and Decipher in 2026? - Management indicated that Afirma is expected to grow in the mid to high single digits, while Decipher is projected to grow approximately 20% [30][90]

Q4 & FY 2025 Earnings Presentation February 25, 2026 © 2026 Veracyte, Inc. All rights reserved. 1 Forward-looking statements and non-GAAP information This presentation contains forward-looking statements, including, but not limited to our statements related to our plans, objectives, and expectations (financial and otherwise), including with respect to our 2025 and 2026 financial and operating results; our assumptions for future revenue growth; plans and timing of the release of version 2 of our Veracyte tra ...